MCID: NTR004
MIFTS: 61

Neutropenia

Categories: Blood diseases, Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Neutropenia

Summaries for Neutropenia

MalaCards based summary: Neutropenia, also known as leukopenia, is related to poikiloderma with neutropenia and cyclic neutropenia. An important gene associated with Neutropenia is ELANE (Elastase, Neutrophil Expressed), and among its related pathways/superpathways are Hematopoietic Stem Cells and Lineage-specific Markers and Other interleukin signaling. The drugs Triamcinolone and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, bone marrow and myeloid, and related phenotypes are immune system and hematopoietic system

Wikipedia: 75 Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood.... more...

Related Diseases for Neutropenia

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Neutropenia, Severe Congenital, 8, Autosomal Dominant Neutropenia, Severe Congenital, 9, Autosomal Dominant
Severe Congenital Neutropenia Severe Congenital Neutropenia 1
Severe Congenital Neutropenia 7 Autosomal Dominant Severe Congenital Neutropenia
Severe Congenital Neutropenia 2 Severe Congenital Neutropenia 5
Severe Congenital Neutropenia 3 Severe Congenital Neutropenia 6
Severe Congenital Neutropenia 8 Severe Congenital Neutropenia 4
Elane-Related Neutropenia Acquired Neutropenia
Autosomal Recessive Severe Congenital Neutropenia

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 1183, show less)
# Related Disease Score Top Affiliating Genes
1 poikiloderma with neutropenia 33.5 USB1 JAGN1 HAX1 G6PC3
2 cyclic neutropenia 33.4 USB1 TAFAZZIN SLC37A4 JAGN1 IL3 HAX1
3 severe congenital neutropenia 33.3 VPS13B SRP54 SLC37A4 JAGN1 IL3 HAX1
4 neutropenia, severe congenital, 3, autosomal recessive 33.1 IL3 HAX1 ELANE CSF3R CSF3 CSF2
5 severe congenital neutropenia 4 33.0 SLC37A4 HAX1 G6PC3
6 severe congenital neutropenia 5 33.0 USB1 SLC37A4 JAGN1 HAX1 GFI1 G6PC3
7 severe congenital neutropenia 7 33.0 USB1 SRP54 JAGN1 HAX1 GFI1 G6PC3
8 severe congenital neutropenia 3 32.9 SLC37A4 JAGN1 HAX1 GFI1 G6PC3 ELANE
9 severe congenital neutropenia 6 32.9 JAGN1 G6PC3
10 autosomal dominant severe congenital neutropenia 32.8 SRP54 SLC37A4 JAGN1 HAX1 GFI1 G6PC3
11 felty syndrome 32.8 IL3 FCGR3B CSF3 CSF2
12 3-methylglutaconic aciduria with cataracts, neurologic involvement and neutropenia 32.7 HAX1 CLPB
13 whim syndrome 1 32.6 HAX1 G6PC3 ELANE CSF3R CSF3
14 shwachman-diamond syndrome 1 32.5 SRP54 HAX1 GFI1 G6PC3 ELANE CSF3R
15 autosomal recessive severe congenital neutropenia 32.4 HAX1 G6PC3
16 cohen syndrome 32.4 VPS13B JAGN1 HAX1 G6PC3
17 leukemia, acute lymphoblastic 32.3 TPMT TOP1 IL3 CSF3R CSF3 CSF2
18 leukemia, acute myeloid 32.3 TOP1 IL3 GFI1 FCGR3B CSF3R CSF3
19 thiopurines, poor metabolism of, 1 31.9 UGT1A1 TPMT DPYD
20 granulocytopenia 31.9 IL3 CSF3 CSF2
21 myelodysplastic syndrome 31.7 TOP1 IL3 FCGR3B CSF3R CSF3 CSF2
22 acute leukemia 31.6 TPMT TOP1 IL3 CSF3R CSF3 CSF2
23 mucositis 31.5 IL3 DPYD CSF3 CSF2
24 hematologic cancer 31.5 TOP1 IL3 CSF3 CSF2
25 deficiency anemia 31.5 TPMT IL3 CSF3R CSF3 CSF2
26 aspergillosis 31.5 ELANE CSF3 CSF2
27 myeloid leukemia 31.4 IL3 CSF3R CSF3 CSF2
28 aplastic anemia 31.3 IL3 CSF3R CSF3 CSF2
29 pancytopenia 31.2 TPMT IL3 G6PC3 CSF3 CSF2
30 stomatitis 31.2 DPYD CSF3 CSF2
31 neutrophilia, hereditary 31.1 IL3 CSF3R CSF3 CSF2
32 diarrhea 31.1 UGT1A1 TOP1 IL3 CSF3
33 leukemia, chronic myeloid 31.0 IL3 FCGR3B ELANE CSF3R CSF3 CSF2
34 bacterial infectious disease 30.9 IL3 FCGR3B ELANE CSF3 CSF2
35 dyskeratosis congenita 30.8 USB1 HAX1 CSF3 CSF2
36 paroxysmal nocturnal hemoglobinuria 30.8 IL3 FCGR3B CSF3R CSF3 CSF2
37 skin disease 30.8 TPMT IL3 FCGR3B CSF3 CSF2
38 bacterial pneumonia 30.7 ELANE CSF3 CSF2
39 peritonitis 30.7 FCGR3B ELANE CSF3
40 gastroenteritis 30.6 IL3 CSF3 CSF2
41 myeloproliferative neoplasm 30.6 IL3 CSF3R CSF3 CSF2
42 thrombocytosis 30.5 IL3 CSF3 CSF2
43 chronic myelomonocytic leukemia 30.5 TOP1 IL3 CSF3R CSF3 CSF2
44 acute promyelocytic leukemia 30.4 IL3 ELANE CSF3R CSF3 CSF2
45 severe covid-19 30.4 FCGR3B CSF3 CSF2
46 hemophagocytic lymphohistiocytosis 30.4 FCGR3B CSF3 CSF2
47 granulomatosis with polyangiitis 30.3 TPMT FCGR3B ELANE
48 critical covid-19 30.1 FCGR3B CSF3 CSF2
49 gilbert syndrome 30.0 UGT1A1 TPMT TOP1 DPYD
50 hemorrhagic cystitis 30.0 TOP1 CSF3
51 blood platelet disease 29.6 IL3 CSF3 CSF2
52 neutropenia, severe congenital, x-linked 11.6
53 barth syndrome 11.6
54 neutropenia, nonimmune chronic idiopathic, of adults 11.5
55 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 11.5
56 neutropenia, severe congenital, 1, autosomal dominant 11.5
57 neutropenia, severe congenital, 5, autosomal recessive 11.5
58 neutropenia, severe congenital, 8, autosomal dominant 11.5
59 neutropenia, severe congenital, 7, autosomal recessive 11.5
60 neutropenia, severe congenital, 9, autosomal dominant 11.4
61 3-methylglutaconic aciduria, type viib 11.4
62 neutropenia, severe congenital, 4, autosomal recessive 11.4
63 clpb deficiency 11.4
64 immunodeficiency 55 11.4
65 3-methylglutaconic aciduria, type viia 11.4
66 neutropenia, severe congenital, 2, autosomal dominant 11.3
67 neutropenia-monocytopenia-deafness syndrome 11.3
68 neonatal alloimmune neutropenia 11.3
69 severe congenital neutropenia 8 11.3
70 neutropenia, chronic familial 11.2
71 severe congenital neutropenia 1 11.2
72 neutropenia, severe congenital, 6, autosomal recessive 11.2
73 immunodeficiency 98 with autoinflammation, x-linked 11.2
74 severe congenital neutropenia 2 11.2
75 transient neonatal neutropenia 11.2
76 lichtenstein syndrome 11.2
77 autosomal recessive severe congenital neutropenia due to cxcr2 deficiency 11.2
78 hermansky-pudlak syndrome due to ap-3 deficiency 11.1
79 thrombocytopenia 1 11.1
80 neutropenia, lethal congenital, with eosinophilia 11.1
81 immunodeficiency 50 11.1
82 acquired neutropenia 11.1
83 wiskott-aldrich syndrome 11.1
84 glycogen storage disease ia 11.1
85 autoimmune lymphoproliferative syndrome 11.0
86 glycogen storage disease ib 11.0
87 pearson marrow-pancreas syndrome 11.0
88 onychotrichodysplasia and neutropenia 11.0
89 immunodeficiency 46 11.0
90 cd40 ligand deficiency 11.0
91 elane-related neutropenia 11.0
92 hermansky-pudlak syndrome 2 11.0
93 evans' syndrome 11.0
94 periodic fever, immunodeficiency, and thrombocytopenia syndrome 11.0
95 propionic acidemia 10.9
96 charcot-marie-tooth disease, dominant intermediate b 10.9
97 transient erythroblastopenia of childhood 10.9
98 immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation 10.9
99 3-methylglutaconic aciduria, type viii 10.9
100 saul-wilson syndrome 10.9
101 immunodeficiency 73b with defective neutrophil chemotaxis and lymphopenia 10.9
102 whim syndrome 2 10.9
103 portal hypertension, noncirrhotic, 2 10.9
104 constitutional neutropenia 10.9
105 t-cell large granular lymphocyte leukemia 10.9
106 immunodeficiency with hyper-igm, type 1 10.9
107 constitutional neutropenia with extra-hematopoietic manifestations 10.8
108 hermansky-pudlak syndrome 10.8
109 fanconi anemia, complementation group a 10.8
110 specific granule deficiency 1 10.8
111 dihydropyrimidine dehydrogenase deficiency 10.8
112 leukemia, acute lymphoblastic 3 10.8
113 diamond-blackfan anemia 10.8
114 bacteremia 2 10.8
115 langerhans cell histiocytosis 10.8
116 griscelli syndrome, type 2 10.8
117 immunodeficiency 68 10.8
118 immunodeficiency 23 10.8
119 acquired agranulocytosis 10.8
120 neonatal lupus erythematosus 10.8
121 ataxia-pancytopenia syndrome 10.8
122 transcobalamin ii deficiency 10.8
123 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.8
124 autoimmune lymphoproliferative syndrome, type iia 10.8
125 immunodeficiency 67 10.8
126 immunodeficiency due to defect in mapbp-interacting protein 10.8
127 purine nucleoside phosphorylase deficiency 10.8
128 hermansky-pudlak syndrome 5 10.8
129 ras-associated autoimmune leukoproliferative disorder 10.8
130 t-cell immunodeficiency, recurrent infections, and autoimmunity with or without cardiac malformations 10.8
131 mitochondrial dna depletion syndrome 13 10.8
132 autoimmune disease, multisystem, infantile-onset, 1 10.8
133 hermansky-pudlak syndrome 10 10.8
134 tubulointerstitial kidney disease, autosomal dominant, 5 10.8
135 shwachman-diamond syndrome 2 10.8
136 bone marrow failure syndrome 6 10.8
137 immunodeficiency 93 and hypertrophic cardiomyopathy 10.8
138 copper deficiency myelopathy 10.8
139 pneumonia caused by pseudomonas aeruginosa infection 10.8
140 dyserythropoietic anemia and thrombocytopenia 10.8
141 hyper-igm syndrome with susceptibility to opportunistic infections 10.8
142 lymphoma, hodgkin, classic 10.7
143 acute myeloid leukemia with recurrent genetic anomaly 10.7
144 thrombocytopenia 10.7
145 lymphoma 10.6
146 toxic shock syndrome 10.6
147 splenomegaly 10.5
148 immune deficiency disease 10.5
149 leukemia 10.5
150 lymphoma, non-hodgkin, familial 10.5
151 eosinophilic gastroenteritis 10.5 IL3 CSF3 CSF2
152 leukocyte disease 10.5 IL3 FCGR3B CSF3 CSF2
153 spastic paraplegia 32, autosomal recessive 10.5 FCGR3B CSF2
154 lymphopenia 10.5
155 coronavirus infectious disease 10.5 FCGR3B CSF3 CSF2
156 oxirane allergy 10.5 IL3 FCGR3B
157 burkitt lymphoma 10.5
158 bronchial disease 10.4 IL3 ELANE CSF2
159 exanthem 10.4
160 macroglossia 10.4 DPYD CSF3
161 glycogen storage disease 10.4
162 thrombocytopenia due to platelet alloimmunization 10.4
163 b-cell lymphoma 10.4
164 g6pc3 deficiency 10.4
165 klebsiella infection 10.4
166 small cell cancer of the lung 10.4
167 viral infectious disease 10.4
168 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.4
169 candidiasis 10.4
170 purpura 10.4
171 systemic lupus erythematosus 10.4
172 glycogen storage disease due to glucose-6-phosphatase deficiency type ib 10.4
173 bone marrow cancer 10.4 IL3 CSF3 CSF2
174 lung cancer 10.4
175 invasive aspergillosis 10.3
176 lupus erythematosus 10.3
177 hypereosinophilic syndrome 10.3
178 periodontitis 10.3
179 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.3
180 autoimmune disease 10.3
181 diffuse large b-cell lymphoma 10.3
182 gingivitis 10.3
183 cellulitis 10.3
184 systemic lupus erythematosus 1 10.3
185 adult respiratory distress syndrome 10.3
186 agammaglobulinemia, x-linked 10.3
187 urinary tract infection 10.3
188 agammaglobulinemia 10.3
189 chronic eosinophilic pneumonia 10.3 CSF3 CSF2
190 hepatitis c 10.3
191 myeloma, multiple 10.3
192 graft-versus-host disease 10.3
193 fungal infectious disease 10.3
194 pneumonia 10.3
195 enterocolitis 10.3
196 vasculitis 10.3
197 rhabdomyosarcoma 2 10.3
198 thrombocytopenic purpura, autoimmune 10.3
199 graves disease 1 10.3
200 acquired immunodeficiency syndrome 10.3
201 colorectal cancer 10.3
202 hemolytic anemia 10.3
203 respiratory failure 10.2
204 otitis media 10.2
205 leukemia, chronic lymphocytic 10.2
206 tatton-brown-rahman syndrome 10.2
207 osteomyelitis 10.2
208 hepatitis 10.2
209 rheumatoid arthritis 10.2
210 mismatch repair cancer syndrome 1 10.2
211 lymphoproliferative syndrome 10.2
212 iron metabolism disease 10.2
213 pfeiffer syndrome 10.2
214 breast cancer 10.2
215 common variable immunodeficiency 10.2
216 bacterial sepsis 10.2
217 brucellosis 10.2
218 graves' disease 10.2
219 ovarian cancer 10.2
220 charge syndrome 10.2
221 myopathy 10.2
222 mucormycosis 10.2
223 pancreatic cancer 10.2
224 pre-eclampsia 10.2
225 multiple sclerosis 10.1
226 covid-19 10.1
227 erythema infectiosum 10.1
228 erythrokeratoderma ''en cocardes'' 10.1
229 oculodentodigital dysplasia 10.1
230 anemia, autoimmune hemolytic 10.1
231 fanconi anemia, complementation group e 10.1
232 tonsillitis 10.1
233 pharyngitis 10.1
234 turner syndrome 10.1
235 hyperthyroidism 10.1
236 amyloidosis 10.1
237 adult syndrome 10.1
238 gastric cancer 10.1
239 ecthyma 10.1
240 lymphadenitis 10.1
241 hairy cell leukemia 10.1
242 severe acute respiratory syndrome 10.1
243 esophageal cancer 10.1
244 inflammatory bowel disease 10.1
245 endocarditis 10.1
246 iron deficiency anemia 10.1
247 appendicitis 10.1
248 chickenpox 10.1
249 aphthous stomatitis 10.1
250 47 xxx syndrome 10.1
251 48,xyyy 10.1
252 large granular lymphocyte leukemia 10.1
253 prostate cancer 10.1
254 sjogren syndrome 10.1
255 infective endocarditis 10.1
256 human cytomegalovirus infection 10.1
257 thalassemia 10.1
258 sarcoma 10.1
259 dengue disease 10.1
260 glomerulonephritis 10.1
261 hemoglobinuria 10.1
262 hypersplenism 10.1
263 bowel dysfunction 10.1
264 hypersensitivity vasculitis 10.1
265 primary agammaglobulinemia 10.1
266 thrombophilia due to thrombin defect 10.1
267 down syndrome 10.1
268 chediak-higashi syndrome 10.1
269 familial mediterranean fever 10.1
270 human immunodeficiency virus type 1 10.1
271 3-methylglutaconic aciduria 10.1
272 allergic disease 10.1
273 exocrine pancreatic insufficiency 10.1
274 aggressive periodontitis 10.1
275 psychotic disorder 10.1
276 hypokalemia 10.1
277 49, xxxxy syndrome 10.1
278 acute graft versus host disease 10.1
279 cytokine deficiency 10.1
280 leukemia, chronic lymphocytic 2 10.0
281 periodontitis, aggressive, 1 10.0
282 adrenocortical carcinoma, hereditary 10.0
283 rothmund-thomson syndrome, type 2 10.0
284 kawasaki disease 10.0
285 colitis 10.0
286 nephrotic syndrome 10.0
287 respiratory syncytial virus infectious disease 10.0
288 hypothyroidism 10.0
289 squamous cell carcinoma 10.0
290 chronic kidney disease 10.0
291 arthritis 10.0
292 perinatal necrotizing enterocolitis 10.0
293 crohn's disease 10.0
294 soft tissue sarcoma 10.0
295 myelofibrosis 10.0
296 hemophagocytic lymphohistiocytosis, familial, 1 10.0
297 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 10.0
298 cervical cancer 10.0
299 ovarian cancer 1 10.0
300 ewing sarcoma 10.0
301 short stature, onychodysplasia, facial dysmorphism, and hypotrichosis 10.0
302 female breast cancer 10.0
303 immunoglobulin alpha deficiency 10.0
304 serum amyloid a amyloidosis 10.0
305 disseminated intravascular coagulation 10.0
306 oral candidiasis 10.0
307 liver cirrhosis 10.0
308 nutritional deficiency disease 10.0
309 severe combined immunodeficiency 10.0
310 herpes zoster 10.0
311 neuropathy 10.0
312 meningitis 10.0
313 children's interstitial lung disease 10.0
314 spondyloarthropathy 1 10.0
315 osteoporosis 10.0
316 schizophrenia 10.0
317 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
318 inflammatory bowel disease 1 10.0
319 prostate cancer, hereditary, 8 10.0
320 prostate cancer, hereditary, 6 10.0
321 malaria 10.0
322 bone mineral density quantitative trait locus 8 10.0
323 bone mineral density quantitative trait locus 15 10.0
324 fusariosis 10.0
325 childhood acute lymphocytic leukemia 10.0
326 pemphigoid 10.0
327 dilated cardiomyopathy 10.0
328 pure red-cell aplasia 10.0
329 heart septal defect 10.0
330 atrial heart septal defect 10.0
331 colonic benign neoplasm 10.0
332 relapsing-remitting multiple sclerosis 10.0
333 rhabdomyosarcoma 10.0
334 thymoma 10.0
335 skin carcinoma 10.0
336 kidney disease 10.0
337 t-cell acute lymphoblastic leukemia 10.0
338 bronchitis 10.0
339 conjunctivitis 10.0
340 end stage renal disease 10.0
341 bullous pemphigoid 10.0
342 neuromyelitis optica 10.0
343 toxoplasmosis 10.0
344 hypoglycemia 10.0
345 candida glabrata 10.0
346 inherited bone marrow failure syndromes 10.0
347 interatrial communication 10.0
348 functional neutrophil defect 10.0
349 behcet syndrome 9.9
350 celiac disease 1 9.9
351 cartilage-hair hypoplasia 9.9
352 osteogenic sarcoma 9.9
353 gallbladder disease 1 9.9
354 anorexia nervosa 9.9
355 pulmonary disease, chronic obstructive 9.9
356 neutrophilic dermatosis, acute febrile 9.9
357 severe cutaneous adverse reaction 9.9
358 follicular lymphoma 9.9
359 childhood acute myeloid leukemia 9.9
360 nk cell deficiency 9.9
361 combined immunodeficiency 9.9
362 pneumocystosis 9.9
363 pulmonary edema 9.9
364 dysgammaglobulinemia 9.9
365 cryptococcosis 9.9
366 cartilage disease 9.9
367 melanoma 9.9
368 dysostosis 9.9
369 cholecystitis 9.9
370 autoimmune hepatitis 9.9
371 dental caries 9.9
372 chronic granulomatous disease 9.9
373 palmoplantar keratosis 9.9
374 toxic encephalopathy 9.9
375 arthropathy 9.9
376 gastritis 9.9
377 liver disease 9.9
378 hyperglycemia 9.9
379 cervical adenitis 9.9
380 congestive heart failure 9.9
381 cataract 9.9
382 herpes simplex 9.9
383 ulcerative colitis 9.9
384 bronchiectasis 9.9
385 polyarteritis nodosa 9.9
386 chronic graft versus host disease 9.9
387 fetal and neonatal alloimmune thrombocytopenia 9.9
388 ovarian epithelial cancer 9.9
389 fetal anticonvulsant syndrome 9.9
390 refractory anemia 9.9
391 leukocyte adhesion deficiency, type i 9.9
392 hashimoto thyroiditis 9.9
393 pneumothorax, primary spontaneous 9.9
394 temporal arteritis 9.9
395 digeorge syndrome 9.9
396 ceroid lipofuscinosis, neuronal, 5 9.9
397 ataxia with vitamin e deficiency 9.9
398 helicobacter pylori infection 9.9
399 body mass index quantitative trait locus 1 9.9
400 patent ductus arteriosus 1 9.9
401 vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome 9.9
402 mantle cell lymphoma 9.9
403 clostridium difficile colitis 9.9
404 head and neck cancer 9.9
405 esophagitis 9.9
406 urticaria 9.9
407 pneumothorax 9.9
408 epilepsy 9.9
409 viral hepatitis 9.9
410 hyperuricemia 9.9
411 acute kidney failure 9.9
412 pyoderma 9.9
413 schizoaffective disorder 9.9
414 peripheral nervous system disease 9.9
415 inherited metabolic disorder 9.9
416 spondylitis 9.9
417 juvenile rheumatoid arthritis 9.9
418 thyroiditis 9.9
419 monoclonal gammopathy of uncertain significance 9.9
420 lymphatic system disease 9.9
421 neuroblastoma 9.9
422 gastrointestinal system disease 9.9
423 septic arthritis 9.9
424 osteoarthritis 9.9
425 fasciitis 9.9
426 alopecia 9.9
427 was-related disorders 9.9
428 albinism 9.9
429 congenital cytomegalovirus 9.9
430 post-transplant lymphoproliferative disease 9.9
431 b-cell non-hodgkin lymphoma 9.9
432 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.9
433 overgrowth syndrome 9.9
434 amyloidosis, familial visceral 9.8
435 coloboma of optic nerve 9.8
436 photoparoxysmal response 1 9.8
437 hypertension, essential 9.8
438 psoriasis 1 9.8
439 sarcoidosis 1 9.8
440 type 1 diabetes mellitus 9.8
441 trichohepatoenteric syndrome 1 9.8
442 myeloperoxidase deficiency 9.8
443 reticular dysgenesis 9.8
444 psoriasis 2 9.8
445 light fixation seizure syndrome 9.8
446 sickle cell anemia 9.8
447 abdominal obesity-metabolic syndrome 1 9.8
448 psoriasis 7 9.8
449 nasopharyngeal carcinoma 9.8
450 creatinine clearance quantitative trait locus 9.8
451 legionnaire disease 9.8
452 psoriasis 11 9.8
453 premature ovarian failure 7 9.8
454 beta-thalassemia 9.8
455 psoriasis 13 9.8
456 mannose-binding lectin deficiency 9.8
457 pulmonary hypertension 9.8
458 oculocutaneous albinism 9.8
459 vitamin b12 deficiency 9.8
460 primary progressive multiple sclerosis 9.8
461 mastoiditis 9.8
462 beta-lactam allergy 9.8
463 cryptococcal meningitis 9.8
464 hypogonadotropic hypogonadism 9.8
465 sensorineural hearing loss 9.8
466 acute pericementitis 9.8
467 chlamydia 9.8
468 goiter 9.8
469 primary biliary cholangitis 9.8
470 leukostasis 9.8
471 uveitis 9.8
472 gout 9.8
473 typhoid fever 9.8
474 klebsiella pneumonia 9.8
475 alcohol use disorder 9.8
476 cystitis 9.8
477 histoplasmosis 9.8
478 calcinosis 9.8
479 hepatitis b 9.8
480 polyclonal hypergammaglobulinemia 9.8
481 dermatitis 9.8
482 bronchiolitis 9.8
483 testicular cancer 9.8
484 gingival overgrowth 9.8
485 skin squamous cell carcinoma 9.8
486 bipolar disorder 9.8
487 central nervous system cancer 9.8
488 thrombophlebitis 9.8
489 systemic scleroderma 9.8
490 rhinitis 9.8
491 adenosine deaminase deficiency 9.8
492 connective tissue disease 9.8
493 myocarditis 9.8
494 chronic rhinitis 9.8
495 collagen disease 9.8
496 pyoderma gangrenosum 9.8
497 measles 9.8
498 subacute delirium 9.8
499 pyomyositis 9.8
500 psoriasis 9.8
501 leishmaniasis 9.8
502 cholangitis 9.8
503 necrotizing fasciitis 9.8
504 haemophilus influenzae 9.8
505 leukemia, t-cell, chronic 9.8
506 neonatal systemic lupus erythematosus 9.8
507 pdgfrb-associated chronic eosinophilic leukemia 9.8
508 traumatic brain injury 9.8
509 germ cell tumor 9.8
510 rare genetic skin disease 9.8
511 chronic bilirubin encephalopathy 9.8
512 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency 9.7
513 alcohol dependence 9.7
514 atrial tachyarrhythmia with short pr interval 9.7
515 gastroesophageal reflux 9.7
516 cone-rod dystrophy 2 9.7
517 dilution, pigmentary 9.7
518 lymphoma, mucosa-associated lymphoid type 9.7
519 hypercholesterolemia, familial, 1 9.7
520 renal cell carcinoma, nonpapillary 9.7
521 endosteal hyperostosis, autosomal dominant 9.7
522 hypertriglyceridemia 1 9.7
523 hypogonadotropic hypogonadism 7 with or without anosmia 9.7
524 kaposi sarcoma 9.7
525 leukemia, acute monocytic 9.7
526 medulloblastoma 9.7
527 myositis 9.7
528 parkinson disease, late-onset 9.7
529 kindler syndrome 9.7
530 pelvic organ prolapse 9.7
531 retinoblastoma 9.7
532 roussy-levy hereditary areflexic dystasia 9.7
533 scleroderma, familial progressive 9.7
534 thyroid cancer, nonmedullary, 1 9.7
535 varicose veins 9.7
536 zinc, elevated plasma 9.7
537 citrullinemia, classic 9.7
538 factor vii deficiency 9.7
539 neurodegeneration with brain iron accumulation 2a 9.7
540 3-methylglutaconic aciduria, type iii 9.7
541 polycythemia vera 9.7
542 smith-lemli-opitz syndrome 9.7
543 testicular germ cell tumor 9.7
544 hypothyroidism, congenital, nongoitrous, 1 9.7
545 squamous cell carcinoma, head and neck 9.7
546 wilson disease 9.7
547 androgen insensitivity syndrome 9.7
548 renal cell carcinoma, papillary, 1 9.7
549 alveolar soft part sarcoma 9.7
550 allergic rhinitis 9.7
551 psoriatic arthritis 9.7
552 spastic paraplegia, ataxia, and mental retardation 9.7
553 endometrial cancer 9.7
554 hepatitis c virus 9.7
555 chromosome 22q11.2 deletion syndrome, distal 9.7
556 cholangitis, primary sclerosing 9.7
557 dengue virus 9.7
558 leptin deficiency or dysfunction 9.7
559 leptin receptor deficiency 9.7
560 melioidosis 9.7
561 cerebellar atrophy, developmental delay, and seizures 9.7
562 lipoprotein quantitative trait locus 9.7
563 angina pectoris 9.7
564 adrenal cortical carcinoma 9.7
565 streptococcus pneumonia 9.7
566 acute diarrhea 9.7
567 cryptogenic organizing pneumonia 9.7
568 erythema multiforme 9.7
569 lambert-eaton myasthenic syndrome 9.7
570 hereditary sensory neuropathy 9.7
571 marginal zone b-cell lymphoma 9.7
572 splenic marginal zone lymphoma 9.7
573 metabolic acidosis 9.7
574 organic acidemia 9.7
575 lung abscess 9.7
576 inguinal hernia 9.7
577 anal fistula 9.7
578 ectopic pregnancy 9.7
579 drug allergy 9.7
580 griscelli syndrome 9.7
581 thrombosis 9.7
582 lymphoblastic lymphoma 9.7
583 chronic neutrophilic leukemia 9.7
584 chronic urticaria 9.7
585 acute asthma 9.7
586 acute myelomonocytic leukemia 9.7
587 aggressive nk-cell leukemia 9.7
588 common cold 9.7
589 charcot-marie-tooth disease 9.7
590 rickets 9.7
591 interstitial nephritis 9.7
592 mastitis 9.7
593 microcephaly 9.7
594 tooth disease 9.7
595 lipoid nephrosis 9.7
596 hydronephrosis 9.7
597 orbital cellulitis 9.7
598 microcytic anemia 9.7
599 erysipelas 9.7
600 gingival recession 9.7
601 pyelonephritis 9.7
602 cicatricial pemphigoid 9.7
603 paranoid schizophrenia 9.7
604 bronchopneumonia 9.7
605 relapsing fever 9.7
606 persistent fetal circulation syndrome 9.7
607 paronychia 9.7
608 focal segmental glomerulosclerosis 9.7
609 severe pre-eclampsia 9.7
610 esophageal candidiasis 9.7
611 congenital dyserythropoietic anemia 9.7
612 eclampsia 9.7
613 polyneuropathy 9.7
614 phaeohyphomycosis 9.7
615 plasmodium falciparum malaria 9.7
616 sclerosing cholangitis 9.7
617 capillary leak syndrome 9.7
618 centronuclear myopathy 9.7
619 angioedema 9.7
620 duodenal ulcer 9.7
621 vascular disease 9.7
622 optic nerve disease 9.7
623 hypogonadism 9.7
624 intestinal perforation 9.7
625 macrocytic anemia 9.7
626 synovitis 9.7
627 bilirubin metabolic disorder 9.7
628 acalculous cholecystitis 9.7
629 proctitis 9.7
630 spinal cord disease 9.7
631 histiocytosis 9.7
632 laryngitis 9.7
633 choriocarcinoma 9.7
634 lactic acidosis 9.7
635 pleural empyema 9.7
636 folliculitis 9.7
637 collecting duct carcinoma 9.7
638 endophthalmitis 9.7
639 brain edema 9.7
640 movement disease 9.7
641 pancreatitis 9.7
642 gingival hypertrophy 9.7
643 acne 9.7
644 peptic ulcer disease 9.7
645 childhood leukemia 9.7
646 scabies 9.7
647 extrinsic allergic alveolitis 9.7
648 polycythemia 9.7
649 lung disease 9.7
650 impetigo 9.7
651 monocytic leukemia 9.7
652 myeloid sarcoma 9.7
653 learning disability 9.7
654 sideroblastic anemia 9.7
655 visceral leishmaniasis 9.7
656 gas gangrene 9.7
657 intracranial hypertension 9.7
658 pulmonary embolism 9.7
659 noma 9.7
660 pik3ca-related overgrowth spectrum 9.7
661 sickle cell disease 9.7
662 acute monoblastic leukemia 9.7
663 anca-associated vasculitis 9.7
664 childhood-onset schizophrenia 9.7
665 coronary artery aneurysm 9.7
666 hemophilia 9.7
667 lip and oral cavity cancer 9.7
668 lymphoma, large-cell, immunoblastic 9.7
669 microscopic polyangiitis 9.7
670 refractory cytopenia with unilineage dysplasia 9.7
671 pulmonary sequestration 9.7
672 systemic onset juvenile idiopathic arthritis 9.7
673 tetraploidy 9.7
674 cytogenetically normal acute myeloid leukemia 9.7
675 encephalopathy 9.7
676 progressive non-infectious anterior vertebral fusion 9.7
677 kindler epidermolysis bullosa 9.7
678 pik3ca-related overgrowth syndrome 9.7
679 mitochondrial disease 9.7
680 autoimmune hemolytic anemia, warm type 9.7
681 pigmentation anomaly of the skin 9.7
682 refractory anemia with excess blasts 9.7
683 refractory cytopenia with multilineage dysplasia 9.7
684 cardiogenic shock 9.7
685 thyroid carcinoma 9.7
686 apnea, obstructive sleep 9.6
687 bladder cancer 9.6
688 campomelic dysplasia 9.6
689 cardiofaciocutaneous syndrome 1 9.6
690 cerebral cavernous malformations 9.6
691 cryoglobulinemia, familial mixed 9.6
692 dermatopathia pigmentosa reticularis 9.6
693 type 2 diabetes mellitus 9.6
694 duane retraction syndrome 1 9.6
695 exudative vitreoretinopathy 1 9.6
696 factor viii deficiency 9.6
697 glioma susceptibility 1 9.6
698 guillain-barre syndrome, familial 9.6
699 hair whorl 9.6
700 hair morphology 2 9.6
701 hepatic adenomas, familial 9.6
702 hernia, hiatus 9.6
703 huntington disease 9.6
704 attention deficit-hyperactivity disorder 9.6
705 inclusion body myositis 9.6
706 lacrimal duct defect 9.6
707 mastocytosis, cutaneous 9.6
708 mitral valve prolapse 1 9.6
709 nondisjunction 9.6
710 myopathy, centronuclear, 1 9.6
711 neuropathy, hereditary, with liability to pressure palsies 9.6
712 ocular cicatricial pemphigoid 9.6
713 spinocerebellar ataxia 1 9.6
714 polyposis, skin pigmentation, alopecia, and fingernail changes 9.6
715 porphyria, acute intermittent 9.6
716 pulmonary hypertension, primary, 1 9.6
717 raynaud disease 9.6
718 smith-magenis syndrome 9.6
719 storm syndrome 9.6
720 tobacco addiction 9.6
721 trigeminal neuralgia 9.6
722 cardiomyopathy, familial hypertrophic, 1 9.6
723 wilms tumor 1 9.6
724 alopecia universalis congenita 9.6
725 conotruncal heart malformations 9.6
726 hypothyroidism, congenital, nongoitrous, 2 9.6
727 cryptorchidism, unilateral or bilateral 9.6
728 cystic fibrosis 9.6
729 endocardial fibroelastosis 9.6
730 eosinophilic fasciitis 9.6
731 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 9.6
732 fanconi anemia, complementation group d2 9.6
733 gaucher disease, type i 9.6
734 hydatidiform mole, recurrent, 1 9.6
735 bernard-soulier syndrome 9.6
736 achalasia-addisonianism-alacrima syndrome 9.6
737 glycogen storage disease ic 9.6
738 heart block, congenital 9.6
739 hydrops fetalis, nonimmune 9.6
740 hypoadrenocorticism, familial 9.6
741 hypoascorbemia 9.6
742 immunodeficiency-centromeric instability-facial anomalies syndrome 1 9.6
743 intracranial hypertension, idiopathic 9.6
744 isovaleric acidemia 9.6
745 papillon-lefevre syndrome 9.6
746 lambert syndrome 9.6
747 leprosy 3 9.6
748 lymphoblastic leukemia, acute, with lymphomatous features 9.6
749 spondylometaphyseal dysplasia, sedaghatian type 9.6
750 microcephaly 1, primary, autosomal recessive 9.6
751 mucolipidosis ii alpha/beta 9.6
752 mucolipidosis iii alpha/beta 9.6
753 proteasome-associated autoinflammatory syndrome 1 9.6
754 nephrotic syndrome, type 1 9.6
755 ceroid lipofuscinosis, neuronal, 1 9.6
756 ocular motor apraxia 9.6
757 pancreatic agenesis 1 9.6
758 hyper-igd syndrome 9.6
759 periodontitis, chronic 9.6
760 scott syndrome 9.6
761 pyle disease 9.6
762 pyruvate carboxylase deficiency 9.6
763 respiratory distress syndrome in premature infants 9.6
764 sea-blue histiocyte disease 9.6
765 thrombocytopenia-absent radius syndrome 9.6
766 methylmalonic aciduria and homocystinuria, cbld type 9.6
767 xeroderma pigmentosum, variant type 9.6
768 adrenal hypoplasia, congenital 9.6
769 tn polyagglutination syndrome 9.6
770 anemia, sideroblastic, 1 9.6
771 multiple congenital anomalies-neurodevelopmental syndrome, x-linked 9.6
772 anemia, sideroblastic, and spinocerebellar ataxia 9.6
773 cardiomyopathy, dilated, 3b 9.6
774 masa syndrome 9.6
775 hemophilia a 9.6
776 menkes disease 9.6
777 intellectual developmental disorder, x-linked, syndromic, turner type 9.6
778 myopathy, centronuclear, x-linked 9.6
779 properdin deficiency, x-linked 9.6
780 androgen insensitivity, partial 9.6
781 kearns-sayre syndrome 9.6
782 budd-chiari syndrome 9.6
783 cardiomyopathy, dilated, 1b 9.6
784 stroke, ischemic 9.6
785 wilms tumor 5 9.6
786 histiocytosis-lymphadenopathy plus syndrome 9.6
787 tumor suppressor gene on chromosome 11 9.6
788 dermatitis, atopic 9.6
789 cerebral cavernous malformations 3 9.6
790 congenital disorder of glycosylation, type iif 9.6
791 urinary tract infections, recurrent 9.6
792 ventricular fibrillation, paroxysmal familial, 1 9.6
793 alpha-thalassemia 9.6
794 orthostatic intolerance 9.6
795 neuropathy, congenital hypomyelinating, 1, autosomal recessive 9.6
796 basal cell carcinoma 1 9.6
797 aneurysmal bone cysts 9.6
798 albinism, oculocutaneous, type iv 9.6
799 hyperinsulinemic hypoglycemia, familial, 6 9.6
800 gastrointestinal stromal tumor 9.6
801 anxiety 9.6
802 immunodeficiency with hyper-igm, type 4 9.6
803 mitochondrial trifunctional protein deficiency 9.6
804 majeed syndrome 9.6
805 hypothyroidism, congenital, nongoitrous, 3 9.6
806 mevalonic aciduria 9.6
807 asthma-related traits 4 9.6
808 pulmonary alveolar proteinosis, acquired 9.6
809 white blood cell count quantitative trait locus 1 9.6
810 diabetes mellitus, ketosis-prone 9.6
811 colorectal cancer 3 9.6
812 sarcoidosis 2 9.6
813 lung cancer susceptibility 3 9.6
814 macs syndrome 9.6
815 agammaglobulinemia 3, autosomal recessive 9.6
816 complement component 9 deficiency 9.6
817 lymphedema, primary, with myelodysplasia 9.6
818 immunodeficiency 21 9.6
819 psoriasis 14, pustular 9.6
820 barrett esophagus 9.6
821 systemic lupus erythematosus 16 9.6
822 hemorrhage, intracerebral 9.6
823 diarrhea 6 9.6
824 human herpesvirus 8 9.6
825 steel syndrome 9.6
826 immunodeficiency 13 9.6
827 immunodeficiency, common variable, 10 9.6
828 b-cell expansion with nfkb and t-cell anergy 9.6
829 immunodeficiency, common variable, 13 9.6
830 mirage syndrome 9.6
831 congenital chloride diarrhea 9.6
832 chronic diarrhea due to guanylate cyclase 2c overactivity 9.6
833 neuronal ceroid-lipofuscinoses 9.6
834 twin-to-twin transfusion syndrome 9.6
835 chlamydia pneumonia 9.6
836 autoimmune pancreatitis 9.6
837 drug-induced lupus erythematosus 9.6
838 chikungunya 9.6
839 aspiration pneumonia 9.6
840 pulmonary aspergilloma 9.6
841 cutaneous lupus erythematosus 9.6
842 penicilliosis 9.6
843 trichosporonosis 9.6
844 hypophosphatemia 9.6
845 multinodular goiter 9.6
846 adult t-cell leukemia/lymphoma 9.6
847 peripheral artery disease 9.6
848 sleep apnea 9.6
849 colorectal adenocarcinoma 9.6
850 withdrawal disorder 9.6
851 good syndrome 9.6
852 pharynx cancer 9.6
853 collagenous colitis 9.6
854 ileitis 9.6
855 ileocolitis 9.6
856 gallbladder disease 9.6
857 adenoid hypertrophy 9.6
858 angular cheilitis 9.6
859 left ventricular noncompaction 9.6
860 penicillin allergy 9.6
861 atypical chronic myeloid leukemia, bcr-abl1 negative 9.6
862 salmonellosis 9.6
863 miliaria crystallina 9.6
864 metaphyseal dysplasia 9.6
865 intestinal pseudo-obstruction 9.6
866 hepatic veno-occlusive disease 9.6
867 primary mediastinal b-cell lymphoma 9.6
868 igg4-related disease 9.6
869 desmoid tumor 9.6
870 hyper ige syndrome 9.6
871 b-lymphoblastic leukemia/lymphoma 9.6
872 bone sarcoma 9.6
873 multisystem inflammatory syndrome in children 9.6
874 erythema nodosum 9.6
875 beta-thalassemia major 9.6
876 complete androgen insensitivity syndrome 9.6
877 histiocytic sarcoma 9.6
878 acute necrotizing pancreatitis 9.6
879 t-cell prolymphocytic leukemia 9.6
880 hepatosplenic t-cell lymphoma 9.6
881 acute myeloid leukemia with myelodysplasia-related changes 9.6
882 pineocytoma 9.6
883 castleman disease 9.6
884 trichothiodystrophy 9.6
885 endometritis 9.6
886 cerebral artery occlusion 9.6
887 osteonecrosis 9.6
888 dermatomyositis 9.6
889 ehrlichiosis 9.6
890 parotitis 9.6
891 sialadenitis 9.6
892 microinvasive gastric cancer 9.6
893 meningoencephalitis 9.6
894 short bowel syndrome 9.6
895 blind loop syndrome 9.6
896 tropical sprue 9.6
897 protein-losing enteropathy 9.6
898 chronic pyelonephritis 9.6
899 portal hypertension 9.6
900 methemoglobinemia 9.6
901 premature menopause 9.6
902 gastric ulcer 9.6
903 hypospadias 9.6
904 borderline personality disorder 9.6
905 hemiplegia 9.6
906 asphyxia neonatorum 9.6
907 henoch-schoenlein purpura 9.6
908 pertussis 9.6
909 anogenital venereal wart 9.6
910 hypoparathyroidism 9.6
911 esophageal varix 9.6
912 t cell deficiency 9.6
913 appendiceal neoplasm 9.6
914 anemia of prematurity 9.6
915 arteriovenous malformation 9.6
916 tetanus 9.6
917 heart disease 9.6
918 suppurative otitis media 9.6
919 laryngostenosis 9.6
920 chondrocalcinosis 9.6
921 retinal vasculitis 9.6
922 listeriosis 9.6
923 portal vein thrombosis 9.6
924 prediabetes syndrome 9.6
925 neonatal diabetes 9.6
926 splenic sequestration 9.6
927 visual epilepsy 9.6
928 hypertrophic cardiomyopathy 9.6
929 alveolar echinococcosis 9.6
930 dengue hemorrhagic fever 9.6
931 dysentery 9.6
932 shigellosis 9.6
933 vulva cancer 9.6
934 hepatitis a 9.6
935 duane retraction syndrome 9.6
936 newborn respiratory distress syndrome 9.6
937 telangiectasis 9.6
938 tolosa-hunt syndrome 9.6
939 quadriplegia 9.6
940 guillain-barre syndrome 9.6
941 subleukemic leukemia 9.6
942 hereditary spherocytosis 9.6
943 conduct disorder 9.6
944 balanitis 9.6
945 hellp syndrome 9.6
946 crescentic glomerulonephritis 9.6
947 brain cancer 9.6
948 nontoxic goiter 9.6
949 nodular goiter 9.6
950 porphyria 9.6
951 mycoplasma pneumoniae pneumonia 9.6
952 congenital toxoplasmosis 9.6
953 megaloblastic anemia 9.6
954 hepatic encephalopathy 9.6
955 coccidioidomycosis 9.6
956 scleritis 9.6
957 osteopetrosis 9.6
958 purulent labyrinthitis 9.6
959 cholestasis 9.6
960 patent foramen ovale 9.6
961 chancroid 9.6
962 miliaria 9.6
963 amenorrhea 9.6
964 schistosomiasis 9.6
965 autoimmune polyendocrine syndrome 9.6
966 iritis 9.6
967 anterior uveitis 9.6
968 bacteriuria 9.6
969 oligospermia 9.6
970 adult-onset still's disease 9.6
971 norwegian scabies 9.6
972 neuroleptic malignant syndrome 9.6
973 dumping syndrome 9.6
974 labyrinthitis 9.6
975 methylmalonic acidemia 9.6
976 echinococcosis 9.6
977 personality disorder 9.6
978 panniculitis 9.6
979 pleural disease 9.6
980 hypersensitivity reaction type iii disease 9.6
981 acute chest syndrome 9.6
982 keratosis 9.6
983 endocrine gland cancer 9.6
984 cheilitis 9.6
985 neuroendocrine carcinoma 9.6
986 bone cancer 9.6
987 gaucher's disease 9.6
988 rectal benign neoplasm 9.6
989 rectum cancer 9.6
990 hyperinsulinism 9.6
991 post-traumatic stress disorder 9.6
992 b cell deficiency 9.6
993 ectodermal dysplasia 9.6
994 vaginitis 9.6
995 granulomatous hepatitis 9.6
996 transient cerebral ischemia 9.6
997 hidradenitis suppurativa 9.6
998 hidradenitis 9.6
999 colon adenocarcinoma 9.6
1000 acromegaly 9.6
1001 blepharoconjunctivitis 9.6
1002 motor peripheral neuropathy 9.6
1003 sensory peripheral neuropathy 9.6
1004 gastric antral vascular ectasia 9.6
1005 basal cell carcinoma 9.6
1006 orchitis 9.6
1007 splenic abscess 9.6
1008 suppurative periapical periodontitis 9.6
1009 familial nephrotic syndrome 9.6
1010 kidney cancer 9.6
1011 transitional cell carcinoma 9.6
1012 pigmented villonodular synovitis 9.6
1013 phimosis 9.6
1014 epidermolysis bullosa 9.6
1015 hemoglobinopathy 9.6
1016 glucosephosphate dehydrogenase deficiency 9.6
1017 acute pancreatitis 9.6
1018 cryoglobulinemia 9.6
1019 membranoproliferative glomerulonephritis 9.6
1020 pulmonary tuberculosis 9.6
1021 kidney papillary necrosis 9.6
1022 germ cell cancer 9.6
1023 glioblastoma 9.6
1024 high grade glioma 9.6
1025 interstitial lung disease 9.6
1026 idiopathic cd4-positive t-lymphocytopenia 9.6
1027 tenosynovial giant cell tumor 9.6
1028 lipid metabolism disorder 9.6
1029 lysosomal storage disease 9.6
1030 demyelinating disease 9.6
1031 tracheal stenosis 9.6
1032 aspiration pneumonitis 9.6
1033 teratoma 9.6
1034 central nervous system disease 9.6
1035 bone inflammation disease 9.6
1036 mesenchymal cell neoplasm 9.6
1037 liposarcoma 9.6
1038 cerebritis 9.6
1039 breast adenocarcinoma 9.6
1040 mastocytosis 9.6
1041 sagittal sinus thrombosis 9.6
1042 gestational trophoblastic neoplasm 9.6
1043 empty sella syndrome 9.6
1044 pericoronitis 9.6
1045 esophagus squamous cell carcinoma 9.6
1046 lung squamous cell carcinoma 9.6
1047 multidrug-resistant tuberculosis 9.6
1048 necrotizing gastritis 9.6
1049 pancreatic adenocarcinoma 9.6
1050 heart valve disease 9.6
1051 syphilis 9.6
1052 glucose metabolism disease 9.6
1053 hypertrichosis 9.6
1054 coronary stenosis 9.6
1055 seminoma 9.6
1056 macular retinal edema 9.6
1057 subacute bacterial endocarditis 9.6
1058 biliary tract cancer 9.6
1059 rapidly progressive glomerulonephritis 9.6
1060 lymph node tuberculosis 9.6
1061 poliomyelitis 9.6
1062 human immunodeficiency virus infectious disease 9.6
1063 epulis 9.6
1064 prolactinoma 9.6
1065 mediastinal cancer 9.6
1066 acute pyelonephritis 9.6
1067 adult acute lymphocytic leukemia 9.6
1068 malignant mesenchymoma 9.6
1069 adult lymphoma 9.6
1070 reactive arthritis 9.6
1071 thyroid hyalinizing trabecular adenoma 9.6
1072 complement deficiency 9.6
1073 progressive bulbar palsy 9.6
1074 hepatoblastoma 9.6
1075 refractory hairy cell leukemia 9.6
1076 stomach disease 9.6
1077 periapical periodontitis 9.6
1078 intestinal obstruction 9.6
1079 ileus 9.6
1080 paralytic ileus 9.6
1081 reticulosarcoma 9.6
1082 scarlet fever 9.6
1083 nervous system disease 9.6
1084 acute megakaryocytic leukemia 9.6
1085 rubella 9.6
1086 intermediate coronary syndrome 9.6
1087 actinic keratosis 9.6
1088 dermatophytosis 9.6
1089 macroglobulinemia 9.6
1090 liver inflammatory pseudotumor 9.6
1091 pemphigus 9.6
1092 herpes zoster oticus 9.6
1093 pompholyx 9.6
1094 cleft lip 9.6
1095 splenic tuberculosis 9.6
1096 lymphangitis 9.6
1097 diabetes mellitus 9.6
1098 status asthmaticus 9.6
1099 acute laryngitis 9.6
1100 epiglottitis 9.6
1101 epididymo-orchitis 9.6
1102 acute myocardial infarction 9.6
1103 blepharitis 9.6
1104 bacterial meningitis 9.6
1105 encephalitis 9.6
1106 babesiosis 9.6
1107 ulcerative stomatitis 9.6
1108 ophthalmia neonatorum 9.6
1109 miliary tuberculosis 9.6
1110 acute biphenotypic leukemia 9.6
1111 bap1 tumor predisposition syndrome 9.6
1112 cartilage-hair hypoplasia - anauxetic dysplasia spectrum disorders 9.6
1113 mitochondrial dna-associated leigh syndrome and narp 9.6
1114 nuclear gene-encoded leigh syndrome spectrum 9.6
1115 periodontal ehlers-danlos syndrome 9.6
1116 acquired hemophilia 9.6
1117 acquired hemophilia a 9.6
1118 acute myeloblastic leukemia with maturation 9.6
1119 acute myeloblastic leukemia without maturation 9.6
1120 cerebellar degeneration 9.6
1121 chromosomal triplication 9.6
1122 clostridium perfringens infection 9.6
1123 clostridium septicum infection 9.6
1124 congenital aplastic anemia 9.6
1125 cote katsantoni syndrome 9.6
1126 fetal parvovirus syndrome 9.6
1127 glioma 9.6
1128 growth hormone deficiency 9.6
1129 hemangioendothelioma 9.6
1130 herpes simplex encephalitis 9.6
1131 immunoglobulin g deficiency 9.6
1132 kikuchi disease 9.6
1133 lymphoma aids related 9.6
1134 lymphosarcoma 9.6
1135 macrophage activation syndrome 9.6
1136 meningococcal infection 9.6
1137 necrobiotic xanthogranuloma 9.6
1138 neurosyphilis 9.6
1139 paroxysmal cold hemoglobinuria 9.6
1140 pediatric t-cell leukemia 9.6
1141 prosthetic joint infection 9.6
1142 pyridoxine deficiency 9.6
1143 secondary adrenal insufficiency 9.6
1144 simple cryoglobulinemia 9.6
1145 thrombasthenia 9.6
1146 virus associated hemophagocytic syndrome 9.6
1147 wells syndrome 9.6
1148 cerebral atrophy 9.6
1149 chronic pain 9.6
1150 febrile seizures 9.6
1151 headache 9.6
1152 hypotonia 9.6
1153 paraneoplastic syndromes 9.6
1154 paresthesia 9.6
1155 tremor 9.6
1156 posttransplant acute limbic encephalitis 9.6
1157 subacute cutaneous lupus erythematosus 9.6
1158 glycogen storage disease due to glucose-6-phosphatase deficiency 9.6
1159 cleft lip/palate 9.6
1160 systemic autoimmune disease 9.6
1161 glial tumor 9.6
1162 immune complex mediated vasculitis 9.6
1163 hemophagocytic syndrome associated with an infection 9.6
1164 hemolytic disease due to fetomaternal alloimmunization 9.6
1165 periodic paralysis 9.6
1166 hereditary poikiloderma 9.6
1167 aggressive b-cell non-hodgkin lymphoma 9.6
1168 acute radiation syndrome 9.6
1169 scedosporiosis 9.6
1170 necrotizing soft tissue infection 9.6
1171 acute monoblastic/monocytic leukemia 9.6
1172 non-histaminic angioedema 9.6
1173 paraquat poisoning 9.6
1174 methotrexate toxicity 9.6
1175 acute liver failure 9.6
1176 diffuse alveolar hemorrhage 9.6
1177 early-onset schizophrenia 9.6
1178 acute adrenal insufficiency 9.6
1179 light and heavy chain deposition disease 9.6
1180 heavy chain deposition disease 9.6
1181 invasive mole 9.6
1182 precursor t-cell acute lymphoblastic leukemia 9.6
1183 twin anemia-polycythemia sequence 9.6

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (showing 47, show less)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Agammaglobulinemia, X-Linked
Anemia, Autoimmune Hemolytic Bladder Cancer
Bronchitis Chronic Kidney Disease
Colorectal Cancer Decubitus Ulcer
Deficiency Anemia Esophageal Cancer
Esophageal Candidiasis Esophagitis
Felty Syndrome Female Breast Cancer
Gastric Cancer Granulomatosis with Polyangiitis
Heart Disease Hepatic Encephalopathy
Hydronephrosis Hypersplenism
Hypothyroidism Immune Deficiency Disease
Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1 Intestinal Obstruction
Iron Deficiency Anemia Leukemia, Chronic Lymphocytic
Main Bronchus Cancer Oral Candidiasis
Ovarian Cancer Paralytic Ileus
Plasma Cell Neoplasm Pneumocystosis
Portal Hypertension Postinflammatory Pulmonary Fibrosis
Primary Thrombocytopenia Protein-Energy Malnutrition
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2 Respiratory Failure
Retinitis Pigmentosa and Erythrocytic Microcytosis Rheumatoid Arthritis
Sideroblastic Anemia Systemic Lupus Erythematosus
Waldenstroem's Macroglobulinemia

Graphical network of the top 20 diseases related to Neutropenia:



Diseases related to Neutropenia

Symptoms & Phenotypes for Neutropenia

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

25 (showing 2, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CLPB CSF2 CSF3 CSF3R DPYD ELANE
2 no effect GR00402-S-2 10.18 CLPB CSF2 CSF3 CSF3R DPYD ELANE

MGI Mouse Phenotypes related to Neutropenia:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.73 CSF2 CSF3 CSF3R ELANE FCGR3B G6PC3
2 hematopoietic system MP:0005397 9.44 CSF2 CSF3 CSF3R ELANE FCGR3B G6PC3

Drugs & Therapeutics for Neutropenia

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 361, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
3
Teicoplanin Approved, Investigational Phase 4 61036-62-2 16170201
4
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
5
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
6
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
7
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415
8
Lenalidomide Approved Phase 4 191732-72-6 216326
9
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
10
Daratumumab Approved Phase 4 945721-28-8
11
Ixazomib Approved, Investigational Phase 4 1072833-77-2 25183872
12
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
13
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
14
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
15
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
16
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Sulfamethoxazole Approved Phase 4 723-46-6 5329
19
Benzylpenicillin Approved, Vet_approved Phase 4 61-33-6 5904
20
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
21
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
22
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
23
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
24
Ofloxacin Approved Phase 4 82419-36-1 4583
25
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
26
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5, 39831-55-5 37768
27
Simvastatin Approved Phase 4 79902-63-9 54454
28
Ceftolozane Approved, Investigational Phase 4 689293-68-3 75984602
29
Letermovir Approved, Investigational Phase 4 917389-32-3 9916099 45138674
30
Lenograstim Approved, Investigational Phase 4 135968-09-1
31
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
32
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
33
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
34
Ribavirin Approved Phase 4 36791-04-5 37542
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
36
Triamcinolone hexacetonide Phase 4
37
Triamcinolone diacetate Phase 4
38
Triamcinolone Acetonide Phase 4 6436
39 glucocorticoids Phase 4
40 Anti-Inflammatory Agents Phase 4
41
Hydroxyitraconazole Phase 4 108222
42 HIV Protease Inhibitors Phase 4
43 Cilastatin, Imipenem Drug Combination Phase 4
44
protease inhibitors Phase 4
45 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
46 Folate Phase 4
47 Vitamin B9 Phase 4
48 Vitamin B Complex Phase 4
49 Anti-Retroviral Agents Phase 4
50 Folic Acid Antagonists Phase 4
51 Antimalarials Phase 4
52 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
53 Penicillin G Procaine Phase 4
54 Penicillin G Benzathine Phase 4
55 Antibiotics, Antitubercular Phase 4
56 Anti-Bacterial Agents Phase 4
57 Anti-Infective Agents Phase 4
58 Amoxicillin-Potassium Clavulanate Combination Phase 4
59 beta-Lactamase Inhibitors Phase 4
60 Cytochrome P-450 Enzyme Inhibitors Phase 4
61 beta-Lactams Phase 4
62 Lactams Phase 4
63 Tin Fluorides Phase 4
64 Penicillins Phase 4
65 Antiviral Agents Phase 4
66 Ceftolozane, tazobactam drug combination Phase 4
67 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
68 Adjuvants, Immunologic Phase 4
69 Immunologic Factors Phase 4
70 Antifungal Agents Phase 4
71 Amebicides Phase 4
72 Antiprotozoal Agents Phase 4
73 Antiparasitic Agents Phase 4
74 Liposomal amphotericin B Phase 4
75 Pharmaceutical Solutions Phase 4
76 Mitogens Phase 4
77 Hematinics Phase 4
78
Epoetin Alfa Phase 4
79 interferons Phase 4
80 Orange Approved Phase 3
81
Tioguanine Approved Phase 3 154-42-7 2723601
82
Aztreonam Approved Phase 3 78110-38-0 5742832
83
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
84
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
85
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
86
Etoposide Approved Phase 3 33419-42-0 36462
87
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
88
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
89
Fluorouracil Approved Phase 3 51-21-8 3385
90
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
91
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
92
Voriconazole Approved Phase 3 137234-62-9 71616
93
Sargramostim Approved, Investigational Phase 3 123774-72-1
94
Plerixafor Approved Phase 2, Phase 3 110078-46-1 65015
95
Lithium carbonate Approved Phase 3 554-13-2
96
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
97
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 3 55-56-1 2713 9552079
98
Vidarabine Approved, Investigational Phase 2, Phase 3 24356-66-9 21704
99
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
100
Idarubicin Approved Phase 3 58957-92-9 42890
101
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
102
Ethanol Approved Phase 3 64-17-5 702
103
Carmustine Approved, Investigational Phase 3 154-93-8 2578
104
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
105
Acyclovir Approved Phase 3 59277-89-3 2022
106
Fosfomycin Approved Phase 3 23155-02-4 446987
107
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
108
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
109
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 2826718
110
Ceftobiprole medocaril Approved, Experimental, Investigational Phase 3 376653-43-9 139292184
111
Ceftobiprole Approved, Investigational Phase 3 209467-52-7 139595999
112
Anidulafungin Approved, Investigational Phase 3 166663-25-8 166548
113
Isotretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4, 4759-48-2 5538 444795 5282379
114
Trichostatin A Experimental Phase 3 58880-19-6 5562 444732
115
Molgramostim Investigational Phase 3 99283-10-0
116 Keratolytic Agents Phase 3
117 Antiemetics Phase 3
118 Gastrointestinal Agents Phase 3
119 Gentamicins Phase 3
120
Etoposide phosphate Phase 3 16760419
121 Vitamins Phase 3
122 Trace Elements Phase 3
123 Antidotes Phase 3
124 Micronutrients Phase 3
125 Protective Agents Phase 3
126 Angiogenesis Inhibitors Phase 3
127 Cola Phase 3
128 Anti-HIV Agents Phase 2, Phase 3
129 Psychotropic Drugs Phase 3
130 Antidepressive Agents Phase 3
131 Disinfectants Phase 3
132 Chlorhexidine gluconate Phase 3
133 Analgesics Phase 3
134 Endothelial Growth Factors Phase 3
135 Alkylating Agents Phase 3
136 Antirheumatic Agents Phase 3
137 Antineoplastic Agents, Alkylating Phase 3
138 Antimitotic Agents Phase 3
139 Tubulin Modulators Phase 3
140 Immunosuppressive Agents Phase 3
141 Liposomal doxorubicin Phase 3
142 Diketopiperazines Phase 3
143 Taxane Phase 3 108169
144
Magnesium oxide Approved Phase 2 1309-48-4 14792
145
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
146
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
147
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
148
Epirubicin Approved Phase 2 56420-45-2 41867
149
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
150
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
151
Isavuconazole Approved, Investigational Phase 2 241479-67-4 21937662
152
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
153
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198
154
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
155
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2
156
Asparaginase Escherichia coli Approved, Investigational Phase 2 9015-68-3
157
Mercaptopurine Approved Phase 2 50-44-2 667490
158
Pegaspargase Approved, Investigational Phase 2 130167-69-0
159
Daunorubicin Approved Phase 2 20830-81-3 30323
160
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
161
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
162
Cobalt Approved, Experimental, Withdrawn Phase 2 7440-48-4 104729
163
Ifosfamide Approved Phase 2 3778-73-2 3690
164
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
165
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
166
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
167
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
168
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
169
Altretamine Approved Phase 2 645-05-6 2123
170
Nevirapine Approved Phase 2 129618-40-2 4463
171
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
172
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
173
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
174
Abatacept Approved Phase 1, Phase 2 332348-12-6
175
Ivosidenib Approved, Investigational Phase 2 1448347-49-6 78140854 71657455
176
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
177
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
178
Thiotepa Approved, Investigational Phase 1, Phase 2 52-24-4 5453
179
Avelumab Approved, Investigational Phase 2 1537032-82-8
180
Empagliflozin Approved Phase 2 864070-44-0 73151030 11949646
181
Melphalan Approved Phase 2 148-82-3 4053 460612
182
Rituximab Approved Phase 2 174722-31-7
183
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
184
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
185
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
186
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
187
Danazol Approved Phase 2 17230-88-5 28417
188
Atorvastatin Approved Phase 2 134523-00-5 60823
189
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
190
Avibactam Approved Phase 2 1192500-31-4
191
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
192
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763
193
Garlic Approved, Nutraceutical Phase 1, Phase 2 8008-99-9
194
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
195
Palifosfamide Investigational Phase 2 31645-39-3 100427
196
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
197
Lintuzumab Investigational Phase 2 166089-32-3
198 Vasoconstrictor Agents Phase 1, Phase 2
199 Bifidobacterium Phase 2
200 Acidophilus Phase 2
201 Anti-Ulcer Agents Phase 2
202 Antacids Phase 2
203 BB 1101 Phase 2
204 topoisomerase I inhibitors Phase 2
205 Agglutinins Phase 2
206 Lectins Phase 2
207 Coagulants Phase 2
208 Radiation-Protective Agents Phase 2
209 Tea Phase 2
210
Angiotensinogen Phase 2 16133225
211 Antihypertensive Agents Phase 2
212 Angiotensin I (1-7) Phase 2
213 Vasodilator Agents Phase 2
214 Cyclosporins Phase 2
215 Astragalus Phase 2
216
2,2'-dithiodiethanesulfonic acid Phase 2 65626
217 Dermatologic Agents Phase 1, Phase 2
218 Calcineurin Inhibitors Phase 2
219 Neuroprotective Agents Phase 2
220
Methylprednisolone Acetate Phase 2 584547
221 Proteasome Inhibitors Phase 2
222 Interleukin 1 Receptor Antagonist Protein Phase 2
223 Immune Checkpoint Inhibitors Phase 1, Phase 2
224 Grapefruit Seed Extract Phase 2
225 Vaccines Phase 1, Phase 2
226 Thymoglobulin Phase 1, Phase 2
227 Antineoplastic Agents, Hormonal Phase 2
228 Hormones Phase 2
229 Hormone Antagonists Phase 2
230 Antimetabolites Phase 2
231 Calcium, Dietary Phase 2
232 Hypolipidemic Agents Phase 2
233 Anticholesteremic Agents Phase 2
234 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
235 Lipid Regulating Agents Phase 2
236 Sodium-Glucose Transporter 2 Inhibitors Phase 2
237 Hypoglycemic Agents Phase 2
238 Estrogens Phase 2
239 Estrogen Receptor Modulators Phase 2
240 Estrogen Receptor Antagonists Phase 2
241 Estrogen Antagonists Phase 2
242 Aromatase Inhibitors Phase 2
243 Selective Estrogen Receptor Modulators Phase 2
244 Liver Extracts Phase 2
245 Androgens Phase 2
246
Rosuvastatin Calcium Phase 2 147098-20-2
247 Avibactam, ceftazidime drug combination Phase 2
248 Antineoplastic Agents, Immunological Phase 2
249 Chrysarobin Phase 2
250
Calcium Nutraceutical Phase 2 7440-70-2 271
251
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
252
Trabectedin Approved, Investigational Phase 1 114899-77-3 108150
253
Zidovudine Approved Phase 1 30516-87-1 35370
254
Clofarabine Approved, Investigational Phase 1 123318-82-1 119182
255
Phenobarbital Approved, Investigational Phase 1 50-06-6 4763
256 Albumin-Bound Paclitaxel Phase 1
257 Reverse Transcriptase Inhibitors Phase 1
258 Neurotransmitter Agents Phase 1
259 Excitatory Amino Acid Antagonists Phase 1
260 Anticonvulsants Phase 1
261 Hypnotics and Sedatives Phase 1
262 GABA Modulators Phase 1
263 Deoxyglucose Phase 1
264 Flt3 ligand protein Phase 1
265
Nicotine Approved 54-11-5 942 89594
266
Azathioprine Approved 446-86-6 2265
267
Idelalisib Approved 870281-82-6 11654566 11625818
268
Cefixime Approved, Investigational 79350-37-1 5362065
269
Ciprofloxacin Approved, Investigational 85721-33-1, 93107-08-5 2764
270
Caffeine Approved 58-08-2 2519
271
Clozapine Approved 5786-21-0 2818 135398737
272
Pemetrexed Approved, Investigational 150399-23-8, 137281-23-3 60843 446556 135565230
273
Mecobalamin Approved, Investigational 13422-55-4
274
Hydroxocobalamin Approved 13422-51-0 15589840 44475014
275
Cloxacillin Approved, Investigational, Vet_approved 61-72-3 6098
276
Warfarin Approved 81-81-2, 129-06-6 54678486
277
Aminocaproic acid Approved, Investigational 60-32-2 564
278
Rocuronium Approved 119302-91-9, 143558-00-3 441290
279
Alfentanil Approved, Illicit 71195-58-9 51263
280
Labetalol Approved 36894-69-6 3869
281
Dopamine Approved 62-31-7, 51-61-6 681
282
Nifedipine Approved 21829-25-4 4485
283
Vecuronium Approved, Investigational 50700-72-6, 86029-43-8 39765 39764
284
Haloperidol Approved 52-86-8 3559
285
Sevelamer Approved 52757-95-6 3085017
286
Spironolactone Approved 1952-01-7, 52-01-7 5833
287
Pentobarbital Approved, Investigational, Vet_approved 76-74-4 4737
288
Tranexamic acid Approved 1197-18-8 5526
289
Diphenhydramine Approved, Investigational 147-24-0, 58-73-1 3100
290
Zolpidem Approved 82626-48-0 5732
291
Ziprasidone Approved 146939-27-7 60854
292
Bosentan Approved, Investigational 147536-97-8 104865
293
Oxycodone Approved, Illicit, Investigational 76-42-6 5284603
294
Nafcillin Approved, Investigational 985-16-0, 147-52-4 8982
295
Molindone Approved 7416-34-4 23897
296
Cidofovir Approved 113852-37-2 60613
297
Promethazine Approved, Investigational 60-87-7 4927
298
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
299
Mitomycin Approved 50-07-7 5746
300
Fludarabine Approved 75607-67-9, 21679-14-1 30751 657237
301
Busulfan Approved, Investigational 55-98-1 2478
302 Coconut Approved
303
Iron Approved 7439-89-6 29936
304
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
305
Ethinylestradiol Approved 57-63-6 5991
306
Polyestradiol phosphate Approved 28014-46-2
307
Norgestimate Approved, Investigational 35189-28-7 6540478
308
Moxifloxacin Approved, Investigational 186826-86-8, 354812-41-2, 151096-09-2 152946
309
Alefacept Approved, Investigational, Withdrawn 222535-22-0
310
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved 65-23-6 1054
311
Cyanocobalamin Approved, Nutraceutical 68-19-9 24892734 16212801 44176380
312
Cobalamin Experimental 13408-78-1 6857388
313 Vitamin B6
314 Vitamin B 6
315 Antipsychotic Agents
316 Vitamin B12
317 Vitamin B 12
318 Radiopharmaceuticals
319 Fluorodeoxyglucose F18
320 Fluoroquinolones
321 Anesthetics
322 Adrenergic beta-Antagonists
323 Adrenergic Antagonists
324 Adrenergic alpha-Antagonists
325 Adrenergic alpha-1 Receptor Antagonists
326 Adrenergic Agents
327 Endothelin Receptor Antagonists
328 Neuromuscular Nondepolarizing Agents
329 Dopamine Antagonists
330 Neuromuscular Blocking Agents
331 Dopamine Agents
332 Anti-Anxiety Agents
333 Antifibrinolytic Agents
334 Anesthetics, Intravenous
335 Anesthetics, General
336 Anticoagulants
337 calcium channel blockers
338
Haloperidol decanoate 52919
339 Analgesics, Opioid
340 GABA Agonists
341
Lurasidone Hydrochloride 367514-88-3
342 Hemostatics
343 Sympathomimetics
344 Diuretics, Potassium Sparing
345 diuretics
346 Tocolytic Agents
347 Narcotics
348 Mineralocorticoids
349 Mineralocorticoid Receptor Antagonists
350 Chelating Agents
351 Antilymphocyte Serum
352 Cytochrome P-450 CYP3A Inhibitors
353 Anti-Infective Agents, Local
354 Estradiol 3-benzoate
355 Estradiol 17 beta-cypionate
356 Contraceptives, Oral, Combined
357 Contraceptives, Oral
358 Contraceptive Agents
359 Norgestimate, ethinyl estradiol drug combination
360
Pyridoxal Experimental, Nutraceutical 66-72-8 1050
361
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(showing 419, show less)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Granulocyte Colony-Stimulating Factor Starting at 24 Hours vs 72 Hours in Pediatric Oncology Patients Unknown status NCT03823950 Phase 4 Granulocyte Colony-Stimulating Factor
2 Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study Unknown status NCT03793205 Phase 4 Long-acting G-CSF;Short-acting G-CSF
3 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
4 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Unknown status NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
5 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
6 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
7 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
8 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
9 Validation of Central Venous (Port A Cath®) Blood Draws for Ciprofloxacin Pharmacokinetic Research in Patients Under Treatment for Childhood Cancer Unknown status NCT02967341 Phase 4
10 G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer Unknown status NCT00030758 Phase 4
11 Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
12 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
13 Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units Completed NCT00709358 Phase 4
14 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
15 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
16 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial. Completed NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
17 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Completed NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
18 A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2) Completed NCT02816164 Phase 4 Neupogen
19 A Multi-Centre Study to Compare Granulocyte-colony Stimulating Factors to Antibiotics for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induced Febrile Neutropenia REaCT-TC2 Completed NCT02816112 Phase 4 Ciprofloxacin;Neupogen
20 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection Completed NCT01401010 Phase 4 Doripenem;doripenem
21 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Following Administration by 4-hour Infusion and Bolus Injection. Completed NCT02213783 Phase 4 Imipenem
22 Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
23 Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer Completed NCT04009941 Phase 4 PEG-rhG-CSF
24 A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
25 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
26 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
27 A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805205 Phase 4 PEG-rhG-CSF
28 The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
29 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
30 Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
31 Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions Completed NCT02621905 Phase 4 Sporanox;Lozanoc
32 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
33 A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
34 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
35 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
36 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
37 Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) Recruiting NCT04233996 Phase 4 Piperacillin-Tazobactam 4 g-0.5 g;Cefepime 2000 mg;Meropenem 1000 mg
38 Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia Recruiting NCT04948463 Phase 4 Piperacillin and Tazobactam for Injection;Cefepime Injection;Ceftazidime Injection;Vancomycin Injection;Amikacin Injection;Ciprofloxacin
39 Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia Recruiting NCT05133310 Phase 4 Simvastatin
40 Evaluation of the Tolerability and Clinical Effectiveness of Letermovir in Heart Transplantation Recruiting NCT04904614 Phase 4 Letermovir
41 Fast-track Absolute Neutrophil Count in Suspected Neutropenic Fever (The FRANCiS-NF Trial): A Single-centre, Pragmatic, Open-label, Randomised, Controlled Trial Recruiting NCT05393505 Phase 4 Meropenem Injection;Levofloxacin;Amoxicillin Clavulanate;Antibiotic
42 CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients; a Single-arm, Single-center, Open-label Clinical Trial (CEF-10 Study) Not yet recruiting NCT05061654 Phase 4 Ceftolozane-tazobactam IV
43 A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients Not yet recruiting NCT05626530 Phase 4 Letermovir
44 Phase III Study of 3 Sequential Doses (10 mg/kg, 5 mg/kg, and 5 mg/kg) vs 3 mg/kg/Day of AmBisome® in the Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics Terminated NCT00421187 Phase 4 Liposomal amphotericin B (AmBisome®)
45 Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia Terminated NCT01859637 Phase 4
46 A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV. Terminated NCT00194857 Phase 4 erythropoietin, GCSF
47 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
48 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
49 Long-acting Versus Short-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Patients: A Multicenter Phase 3 Randomized Controlled Study Unknown status NCT04101760 Phase 3 Long-acting granulocyte colony stimulating factor;Short-acting granulocyte colony stimulating factor
50 A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) on the Incidence of Neutropenia in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Myelosuppressive Chemotherapy Unknown status NCT01560195 Phase 3 Pegylated rhG-CSF: 100µg/kg;Pegylated rhG-CSF: 6mg;placebo and rhG-CSF 5ug/kg/d
51 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
52 The Study of Evaluating the Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia Unknown status NCT02761460 Phase 3 PEG-rhG-CSF
53 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
54 A Randomized, Multicenter Clinical Trial to Determine the Efficacy, Safety and Tolerability of Peg-filgrastim (Gema) Compared to Peg-filgrastim (Roche) for Prevention of Chemotherapy Induced Neutropenia in Patients With Breast Cancer Unknown status NCT03404752 Phase 3 Peg-Filgrastim
55 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
56 Pegfilgrastim on Day +3 Compared to Day +1 for Patients With Refractory or Relapsed Aggressive Lymphoma Receiving Salvage Chemotherapy - a Randomized Controlled Trial Unknown status NCT02238873 Phase 3 Pegfilgrastim
57 Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy Completed NCT02467868 Phase 3
58 A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulasta(R), Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia Completed NCT02044276 Phase 3 lipegfilgrastim;pegfilgrastim
59 High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes) Completed NCT00627393 Phase 3 Standard antimicrobial therapy;G-CSF/dexamethasone
60 A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy Completed NCT01611051 Phase 3 Drug: Pegylated rhG-CSF: 100µg/kg;Pegylated rhG-CSF: 6mg;rhG-CSF 5ug/kg/day
61 Primary G-CSF Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Breast Cancer Patients at Risk of Febrile Neutropenia Completed NCT00536081 Phase 3 pegfilgrastim
62 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
63 Randomized Controlled Trial Comparing Ciprofloxacin With Cefepime in Febrile Neutropenic Patients With Hematologic Diseases Completed NCT00137787 Phase 3 ciprofloxacin;cefepime
64 A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections Completed NCT00035425 Phase 3 linezolid;vancomycin
65 A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia Completed NCT04174599 Phase 3
66 Moderate Persistent Neutropenia: Comparison of Administration of G-CSF (Granulocyte Colony Stimulating Factor) 1 Day Out of 2 Versus Traditional Schedules to Maintain Dose Intensity. Phase III Multicenter Study in Patients With Solid Tumors Receiving Chemotherapy Completed NCT00770172 Phase 3
67 RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE) Completed NCT02643420 Phase 3 SPI-2012;Pegfilgrastim;Docetaxel;Cyclophosphamide
68 Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy Completed NCT02104830 Phase 3
69 A Non-Comparative, Multicenter, Open-Label, Study to Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia Completed NCT00548080 Phase 3 MK0991, caspofungin acetate / Duration of Treatment:
70 A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia Completed NCT04554056 Phase 2, Phase 3 MW05;PEG-rhG-CSF
71 A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1) Completed NCT03102606 Phase 3 Plinabulin;Pegfilgrastim
72 Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER) Completed NCT02953340 Phase 3 SPI-2012;Pegfilgrastim;Docetaxel;Cyclophosphamide
73 A Noncomparative, Multicenter, Open-Label, Study to Evaluate the Safety, Tolerability and Efficacy of MK0991 as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia Completed NCT00379964 Phase 3 caspofungin acetate
74 Evaluation of Lithium Efficacy Against Chemotherapy Induced Neutropenia in Breast Cancer Patients Completed NCT05221593 Phase 3 Lithium Carbonate
75 A Randomized, Double-blind, Parallel Study Comparing Efficacy and Safety of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Prevention of Chemotherapy (Accelerated AC Regimen)Induced Neutropenia in Breast-cancer Patients. Completed NCT03381417 Phase 3 pegcyte;Neulastim
76 A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects With Advanced Breast Cancer Treated With Single Agent Docetaxel Completed NCT00035594 Phase 3 pegfilgrastim
77 Randomized Comparison Between Antibiotics Alone and Antibiotics Plus Granulocyte-Colony Stimulating Factor in Pediatric Patients With Chemotherapy Induced Febrile Neutropenia Completed NCT00003739 Phase 3
78 Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial. Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
79 An Open Label, Randomised, Multicentre Study of Pegfilgrastim in Primary Versus Secondary Prophylaxis of Neutropenia as an Adjunct to Chemotherapy in Elderly Subjects With High Risk Breast Cancer. Completed NCT00117910 Phase 3 pegfilgrastim
80 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
81 Randomized, Open, Multi-Center, Phase III Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy Completed NCT01674855 Phase 3 PEG-G-CSF;G-CSF
82 A Phase III, Non-inferiority Study Comparing Two Filgrastim Preparations in Preventing Chemotherapy Induced Neutropenia in Breast Cancer Completed NCT01079676 Phase 3 Filgrastim (Eurofarma);Filgrastim (Granulokine, Amgen)
83 A Randomized,Multi-center,Parallel-group, Phase II(Single-blind)/Phase III(Double- Blind)Study to Determine the Optimal Dose and to Evaluate the Efficacy and Safety of GCPGC on Chemotherapy-induced Neutropenia Compared to Neulasta(Pegfilgrastim) Completed NCT01328938 Phase 2, Phase 3
84 The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial Completed NCT02251977 Phase 3 GM1;placebo;mFOLFOX6 or XELOX
85 A Phase 3 Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on Myelosuppressive Therapy for Non Myeloid Malignancies. Completed NCT00776165 Phase 3
86 A Randomized Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel) Completed NCT00837265 Phase 2, Phase 3 Pegfilgrastim;Chemotherapy
87 A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients Completed NCT00044486 Phase 3 Posaconazole oral suspension
88 A Randomized Controlled Study Comparing Different Doses of Pegfilgrastim as Support for Adjuvant Chemotherapy for Breast Cancer Completed NCT05283616 Phase 3 Pegfilgrastim
89 Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism Completed NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
90 A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer Completed NCT00001338 Phase 3 FLAC chemotherapy with GM-CSF
91 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI) Completed NCT00911170 Phase 3 Pegfilgrastim;Placebo;Standard Chemotherapy
92 A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Neugranin or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy Completed NCT01126190 Phase 3 Chemotherapy
93 Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% to Reduce the Rate Oral Colonization by Gram-negative Bacteria in Patients With Chemotherapy Completed NCT02414581 Phase 3 chlorhexidine 0.12%/Ethyl alcohol 7%;Ethyl Alcohol 7%;Chlorhexidine 2%/Ethyl alcohol 7%
94 Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
95 Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF Completed NCT00213759 Phase 3 filgrastim;dextrose 5%
96 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
97 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
98 A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed NCT03252431 Phase 3 F-627;Neulasta
99 A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome. Completed NCT02231879 Phase 2, Phase 3 Plerixafor;G-CSF
100 A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed NCT02872103 Phase 3 F-627;Placebo
101 A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy Completed NCT01519700 Phase 3 EP2006;Filgrastim
102 A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01371656 Phase 3 levofloxacin
103 Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta® Completed NCT01516736 Phase 3 LA-EP2006;Neulasta®
104 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
105 A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy Completed NCT01735175 Phase 3 LA-EP2006;Neulasta®
106 Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient Completed NCT00855309 Phase 3 acyclovir sodium
107 The Effects of Compound Herbal Formula(TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy Completed NCT01142479 Phase 2, Phase 3 Chinese herbal medicine decoction
108 A Randomized, Open Label Parallel Controlled, Multicenter Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension Vs. Fluconazole (Capsule) in High-risk Leukopenic Patients for Prevention of Invasive Fungal Infection Completed NCT00811928 Phase 3 Posaconazole;Fluconazole
109 Long-acting Granulocyte Colony Stimulating Factor for the Prevention Febrile Neutropenia in Epithelial Ovarian Cancer: A Phase 3 Randomized Control Study Recruiting NCT03740464 Phase 3 long-acting granulocyte colony stimulating factor;Short-term granulocyte colony stimulating factor
110 A Multicenter Randomized Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia in Hematological Patients: Efficacy and Microbiological Safety Recruiting NCT05311254 Phase 3 Fosfomycin Calcium
111 A Phase 3, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2) Active, not recruiting NCT03294577 Phase 3 Pegfilgrastim;Plinabulin;Docetaxel, doxorubicin, and cyclophosphamide (TAC)
112 A Multicenter, Open-label, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Amphotericin B Liposome for Injection in Patients With Persistent Febrile Neutropenia Not yet recruiting NCT05108545 Phase 3 Amphotericin B liposomes
113 Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: a Randomized Controlled Study -DALFEN Study Terminated NCT03003273 Phase 3
114 A Single Center, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Daptomycin Versus Placebo in Patients With Neutropenia and Fever. Terminated NCT01216241 Phase 3 Daptomycin
115 Multicenter, Randomized, Double-Blind Study of Ceftobiprole Versus Comparators in the Treatment of Patients With Fever and Neutropenia Terminated NCT00529282 Phase 3 Ceftobiprole Medocaril;Cefepime with or without vancomycin
116 A Prospective Multi-Center Study on Pediatric Patients With Fever in Severe Chemotherapy Induced Neutropenia, Including a Randomized Comparison of Outpatient Management and Oral Antimicrobial Therapy Versus Inpatient Management and Intravenous Antimicrobial Therapy in a Subgroup With Low Risk of Adverse Events (Low-Risk Subgroup Study) Terminated NCT00107081 Phase 3 ciprofloxacin and amoxicillin;i.v. antibiotics
117 Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection Terminated NCT00806351 Phase 3 Active Anidulafungin;Active Caspofungin
118 Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial. Withdrawn NCT04698057 Phase 3 Placebo;Amoxicillin Clavulanate;Ciprofloxacin
119 Fever and Neutropenia in Pediatric Oncology Patients: A Randomized, Controlled, Multi-Center Study of Outpatient Therapy Evaluation of Genomic and Proteomic Correlates Withdrawn NCT03768869 Phase 3 Low Risk: Oupatient Management;Low Risk: Inpatient Management;High Risk: Inpatient Management
120 Russian Single-center Open Randomized Clinical Trial of the Impact of Mesenchymal Stromal Cells Therapy on Organ Dysfunction and 28-day Mortality in Patients With Septic Shock and Severe Neutropenia. Unknown status NCT01849237 Phase 1, Phase 2 Standard therapy of septic shock
121 EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18 Unknown status NCT03104595 Phase 2 EC-18
122 Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose Unknown status NCT02544685 Phase 2
123 A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia Unknown status NCT01658956 Phase 2 GCSF administration on days 8 and 12 after chemotherapy
124 A Controlled Study to Determine The Clinical Efficacy Of Garlic Compounds In Patients With Chemotherapy Related Febrile Neutropenia Unknown status NCT00247039 Phase 1, Phase 2
125 Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia in Pediatric Oncology Patients Treated With Cisplatin-Based Chemotherapy: Randomized Clinical Trial Unknown status NCT03449693 Phase 2
126 Evaluation of the Safety and Efficacy of Empagliflozin Administration as a Treatment for Neutropenia in Patients With Glycogenosis Type 1b and G6PC3 Deficiency Unknown status NCT04138251 Phase 2 Empagliflozin
127 Efficacy and Safety of Pegteograstim on Chemotherapy-induced Neutropenia in Children With Solid Tumors Unknown status NCT02787876 Phase 2 Pegteograstim
128 Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia Unknown status NCT01918241 Phase 2 pegfilgrastim,30mcg/kg;pegfilgrastim, 60mcg/kg;pegfilgrastim, 100mcg/kg;filgrastim, 5mcg/kg
129 A Phase I/II Double-Blind, Randomized, Placebo-Control Pilot Study to Evaluate the Safety and Pharmacodynamic Activities of EW02 in Reducing Neutropenia Caused by Breast Cancer Chemotherapy Unknown status NCT00555516 Phase 1, Phase 2
130 Efficacy and Safety of PEGylated Recombinant Human Granulocyte Stimulating Factor in the Prevention of Neutropenia During Concurrent Chemoradiotherapy for Cervical Cancer Unknown status NCT04542356 Phase 2 PEG-rhG-CSF;rhG-CSF
131 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT01417169 Phase 2 micafungin
132 A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer. Unknown status NCT00501332 Phase 2
133 Protocol for Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantron Followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin and Decadron Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
134 Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia Unknown status NCT00243165 Phase 2
135 Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients Unknown status NCT01359501 Phase 2 Chinese medical treatment-LCH1;Placebo
136 Adjuvant Treatment of EC/TC Versus EC/TC Plus Danggui Buxue Decoction in Breast Cancer:A Prospective, Randomized Trial Completed NCT02005783 Phase 2 DBD;Epirubicin;Cyclophosphamide;Docetaxel
137 A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF as Supportive Therapy to Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy Completed NCT02119715 Phase 2 Pegylated rhG-CSF 100μg/kg;Pegylated rhG-CSF:150 μg/kg;rhG-CSF 5 μg/kg/day
138 A Randomized Phase II, Multi-center, Non-inferiority Clinical Trial for Efficacy and Safety of Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases Completed NCT01344681 Phase 2 Micafungin sodium;Itraconazole
139 Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Completed NCT04227990 Phase 2 Plinabulin;Pegfilgrastim;Docetaxel, doxorubicin, and cyclophosphamide (TAC)
140 A Randomised, Double-Blind, Placebo-Controlled, Parallel-Design, Multi-Center Study to Investigate the Efficacy To Reduce Chemotherapy-Induced Neutropenia (CIN), Effects on the Haematopoietic System, Safety and Pharmacokinetics of Myelo001 in Patients Receiving Adjuvant or Neoadjuvant Chemotherapy for the Treatment Of Breast Cancer Completed NCT02692742 Phase 2 Myelo001;Placebo
141 Multi-Center, Randomized, Open, Phase II Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy Completed NCT01923545 Phase 2 PEG-G-CSF;G-CSF
142 A Phase II Study of Isavuconazole Prophylaxis in Adult Patients With AML/MDS and Neutropenia Completed NCT03019939 Phase 2 Isavuconazole
143 Phase II, Multicenter Study Evaluating G-CSF as Primary Prophylaxis for Neutropenia Associated With First-line Chemotherapy Regimen FOLFIRI and Bevacizumab in Patients With Metastatic Colorectal Cancer Who Are Homozygous for UGT1A1*28 Polymorphism, the Promoter of the Gene Encoding for the Enzyme UGT1A1 Completed NCT00541125 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
144 A Phase 2, Multicenter, Randomized Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Completed NCT04345900 Phase 2 Plinabulin;Pegfilgrastim
145 Double Blind, Randomized, Placebo-controlled, Multicenter Pilot Study on Efficacy and Safety of CBLB612 Following Single Administration for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Myelosuppressive Chemotherapy Completed NCT02778763 Phase 2 CBLB612;Placebo
146 Multi-center, Randomized, Open-labeled, Positive-controlled, Phase Ⅱ Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy. Completed NCT02005458 Phase 2 YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle;YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle;YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle;PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
147 An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia Completed NCT00497809 Phase 2 AVI-014 versus Filgrastim
148 A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in Pediatric Patients With Persistent Fever and Neutropenia Completed NCT00082537 Phase 2 caspofungin acetate;Comparator: AmBisome
149 Safety and Efficacy of Interleukin-1 Inhibitor Anakinra for the Amelioration of Fever During Neutropenia and Mucositis in Patients With Multiple Myeloma Receiving an Autologous Stem Cell Transplantation After High-dose Melphalan Completed NCT03233776 Phase 2 Anakinra
150 Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy Completed NCT00604201 Phase 2
151 A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia Completed NCT01615809 Phase 2 AMPHOTERICIN B
152 Phase II Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia Completed NCT00138736 Phase 2 Mannan Binding Lectin (MBL);Mannan Binding Lectin
153 A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma Completed NCT00364468 Phase 2 pegfilgrastim
154 A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 24 Months With New Onset Fever and Neutropenia Completed NCT00292071 Phase 2 caspofungin acetate
155 Phase I-II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Neutropenia Completed NCT00068471 Phase 1, Phase 2 anidulafungin
156 Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia Completed NCT00056381 Phase 1, Phase 2 Anidulafungin
157 A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection Completed NCT00002126 Phase 2 Filgrastim
158 Randomized Multicenter Open-label Phase II Clinical Study Comparing the Efficacy and Safety of the Single Dose of Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy Completed NCT01569087 Phase 2
159 Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen Completed NCT01724866 Phase 2 SPI-2012;Pegfilgrastim;Docetaxel;Cyclophosphamide
160 An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia Completed NCT02282215 Phase 2
161 Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series Completed NCT00392951 Phase 1, Phase 2 sirolimus
162 LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy Completed NCT04562922 Phase 2
163 A Single-arm, Multiple-Dose, Steady-State, Bioavailability Study With Twice Daily Dosing of Lozanoc™ (65 mg Itraconazole Capsules, Mayne) Taken Regardless of Food Completed NCT02755857 Phase 2 Lozanoc
164 Ph IIb Study Evaluating the Safety & Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma Completed NCT00771810 Phase 2 TXA127;Placebo
165 Effect of Using Supragingival Irrigators Containing Chlorhexidine on Oral Health in Patients With Blood Dyscrasia Completed NCT01974401 Phase 2
166 PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy Completed NCT03314805 Phase 2 Astragalus polysaccharides 500 mg;Placebo
167 Evaluation of the Efficacy of Adding Daily G-CSF (Granulocyte Colony Stimulating Factor) for Prevention of Hematologic Toxicity Due to Neoadjuvant or Adjvuant Chemotherapy in Breast Cancer Completed NCT00771433 Phase 2
168 Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor Completed NCT00730314 Phase 1, Phase 2
169 An Open-label, Intravenous to Oral Switch, Multiple Dose Multi-Centre Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Hospitalized Children Aged 2 to 12 Years Who Require Treatment for the Prevention of Systemic Fungal Infections. Completed NCT00174473 Phase 1, Phase 2 Voriconazole
170 A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00077311 Phase 2 cisplatin;docetaxel;BNP7787
171 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
172 TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FIRST COMPLETE REMISSION Completed NCT00002665 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate
173 A Multi-center, Randomized, Open-label, Active-controlled, Dose Finding Study to Evaluate the Efficacy and Safety of F-627 Compared to Filgrastim in Women With Breast Cancer Receiving Myelotoxic Chemotherapy. Completed NCT02521441 Phase 2
174 Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia Completed NCT00031980 Phase 2 cyclosporine
175 INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY Completed NCT00002643 Phase 2 amifostine trihydrate;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
176 A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed NCT01648322 Phase 2 F-627;Neulasta® (pegfilgrastim)
177 A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients Completed NCT00035620 Phase 2 pegfilgrastim;filgrastim
178 A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma Completed NCT00004192 Phase 2 cisplatin;cytarabine;etoposide;methylprednisolone
179 Efficacy and Safety Phase IIb Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Breast Cancer Patients Completed NCT03251768 Phase 2 rHSA-GCSF 2.4mg;GCSF
180 A Phase I, Single Center, Open-label, Dose Escalation Study of Recombinant Human Granulocyte Colony-stimulating Factor Fc Fusion Protein (F-627) in Breast Cancer Patient Receiving Adjuvant Chemotherapy Completed NCT02527746 Phase 1, Phase 2 EC regimen
181 Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever Completed NCT00335478 Phase 2 Daptomycin
182 Bone Marrow Stem Cell Transplantation for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myeloid Leukemia in 1Remission Completed NCT00305708 Phase 1, Phase 2 busulfan;fludarabine phosphate
183 Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia Completed NCT00301834 Phase 2 busulfan;cyclosporine;fludarabine phosphate;methotrexate;methylprednisolone
184 A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab Completed NCT00260689 Phase 2 Cyclosporine;Alemtuzumab
185 A Randomized, Double-Blind, Phase 2 Study Evaluating the Safety of Same Day Versus Next Day Administration of Pegfilgrastim With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) in Women With Breast Cancer Completed NCT00115414 Phase 2 pegfilgrastim;docetaxel;doxorubicin;cyclophosphamide
186 Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin "7+3" Regimen Completed NCT00004215 Phase 2 cytarabine;daunorubicin hydrochloride
187 PHASE II STUDY OF HIGH DOSE CYTARABINE COMBINED WITH A SINGLE HIGH DOSE OF IDARUBICIN FOR NEWLY DIAGNOSED PATIENTS WITH AML: THE AML-3 PROTOCOL Completed NCT00002800 Phase 2 cytarabine;etoposide;idarubicin
188 A Phase Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of F-627 as Prophy